Target intelligence / Profile preview

RBMS3 antisense RNA 2 (RBMS3-AS2)

Target
RBMS3-AS2
Molecular classification
Other (long non-coding RNA / antisense RNA)
01

Overview

RBMS3 antisense RNA 2 (RBMS3-AS2) is a long non-coding RNA (lncRNA) transcribed from the antisense strand at the RBMS3 locus. It is a non-coding transcript, meaning it does not encode a protein, and is classified as an antisense RNA based on its orientation relative to the RBMS3 gene. While its precise function is not fully established in the literature, antisense lncRNAs like RBMS3-AS2 are typically involved in regulation of gene expression, often through post-transcriptional or epigenetic mechanisms. There is currently no evidence that RBMS3-AS2 itself acts as a direct therapeutic target, receptor, enzyme, transporter, or similar pharmacologically actionable entity. Its main research interest is related to the regulation of its sense gene, RBMS3, which is a known RNA-binding protein with tumor suppressor properties, especially in cancer progression and metastasis[4]. No drugs, mechanism of action, biomarkers, or therapeutic safety concerns have been linked directly to RBMS3-AS2. *Note: Most information available in the literature is about the RBMS3 protein and not about RBMS3-AS2; thus, RBMS3-AS2's functional details remain largely uncharacterized in current databases and publications. The entry is not misspelled or incorrect, but it should be clearly distinguished from the protein-coding gene RBMS3[2][4].*

Other names
RBMS3-AS2RBMS3 antisense RNA 2 (non-protein coding)
02

Biological functions

Gene expression regulationpossible post-transcriptional regulation
03

Disease associations

Cancer (implicated in regulation)Other (research context)

Beyond the preview

Go deeper on RBMS3 antisense RNA 2 (RBMS3-AS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBMS3 antisense RNA 2 (RBMS3-AS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call